Thrombolytic use in select stroke patients with recent direct oral anticoagulant (DOAC) ingestion did not raise the risk of the most feared bleeding complication, according to the largest-yet ...

The prevalence of inappropriate direct oral anticoagulant (DOAC) dosing in patients with atrial fibrillation (AF) was 25%. Several demographic factors such as advanced age, presence of chronic kidney ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Despite concerns ...

Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions HealthDay News — Early adoption of the direct oral anticoagulant (DOAC) ...

In patients with atrial fibrillation with low thrombosis risk but high bleeding risk, both standard- and low-dose DOACs are equally effective and safe. Standard-dose direct oral anticoagulant therapy ...

Prescriptions for treatment of atrial fibrillation (AF) and chronic kidney disease (CKD) have primarily been prescriptions for direct oral anticoagulants (DOACs), displacing warfarin as the primary ...

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those approved for stroke prevention, whether higher or ...

To analyze the primary outcomes, DOAC users were matched 1:1 without replacement to a warfarin user. The primary effectiveness outcome was a composite of ischemic stroke or SE. Primary safety outcome ...

The DOAC Dipstick (DOASENSE GmbH) is a single-use, point-of-care dipstick test that is used to detect direct oral anticoagulants (DOACs) in urine. The urine dipstick test detects DOACs (both factor Xa ...

There is high certainty that double therapy with a direct oral anticoagulant (DOAC) and a P2Y12 inhibitor reduces bleeding in A-fib patients who have undergone PCI compared with triple therapy that ...

Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants ...

The direct oral anticoagulants edoxaban, apixaban, rivaroxaban and dabigatran have been recently approved for the treatment of non-valvular atrial fibrillation The new direct oral anticoagulants ...